Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2019 - 2026)

Atea Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $267.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 39.3% year-over-year to $267.1 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 30.91% decrease from a year earlier, with the FY2025 full-year figure at $315.2 million, down 32.16% from the prior year.
• Liabilities and Shareholders Equity declined to $267.1 million in Q1 2026 per AVIR's latest filing, from $315.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $717.2 million in Q1 2022 and bottomed at $267.1 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $553.0 million (2024), against an average of $529.9 million.
• Across the five-year window, Liabilities and Shareholders Equity decreased 9.84% in 2023 and plunged 39.3% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $666.7 million in 2022, then dropped by 10.76% to $595.0 million in 2023, then dropped by 21.9% to $464.7 million in 2024, then slumped by 32.16% to $315.2 million in 2025, then declined by 15.27% to $267.1 million in 2026.
• Per Business Quant, the three latest AVIR Liabilities and Shareholders Equity figures stand at $267.1 million (Q1 2026), $315.2 million (Q4 2025), and $343.0 million (Q3 2025).